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ABSTRACT
Drug-induced liver injury (DILI) accounts for 20–40% of cases of fulminant hepatic failure. Antitubercular therapy (ATT) may cause hepatotoxicity 
which can range from transient asymptomatic rise in liver enzymes to acute liver failure. The drugs in ATT responsible for hepatotoxicity include 
isoniazid, rifampicin, and pyrazinamide. Case series was done to present three different cases of ATT-induced hepatotoxicity which came to the 
Clinical Pharmacology and Therapeutics Department in NIMS for management.
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INTRODUCTION
Drug-induced liver injury (DILI) is one of the most important reasons for 
discontinuation of drugs and treatment failures. Antitubercular therapy 
(ATT) accounts for 58% of cases of DILI, followed by anti-epileptics.
ATT-induced DILI is suspected when in the absence of symptoms, 
elevation of transaminases up to 5 times upper limits of normal (ULN) 
and in the presence of symptoms up to 3 times ULN or twice ULN of 
bilirubin, provided competing causes such as acute viral hepatitis, 
autoimmune hepatitis, and other liver diseases that are ruled out [1].
Among the first-line drugs, isoniazid (H), rifampicin (R), and 
pyrazinamide (Z) have potential for hepatotoxicity, pyrazinamide being 
the most hepatotoxic followed by isoniazid and rifampicin. DILI pattern 
can be hepatocellular or cholestatic or autoimmune of infiltrative types. 
ATT-induced liver damage is hepatocellular type (characterized by 
predominant elevation of transaminases). ATT-induced DILI is due to 
metabolic idiosyncrasy due to metabolites released or accumulated 
during the metabolic process. This may facilitated by genetic factors or 
polymorphism of drug metabolizing enzymes.
The various risk factors for DILI caused by anti-tubercular drugs 
include advanced age, female gender, pregnancy, comorbidities such 
as obesity, diabetes, and underlying liver disease, genetic factors 
such as acetylator polymorphism, concomitant viral infections such 
as HIV, hepatitis B and C, and underlying nutritional status such as 
malnutrition/hypoalbuminemia [2].
CASE NUMBER 1
A 20-year-old male patient was a known case of Koch’s and Gilbert 
syndrome for 3 years and was on antitubercular treatment. After 
3 years of ATT, his total bilirubin increased to 2.6 mg/dl (normal 
limits 0.1–0.8 mg/dl) and there was increase in conjugated bilirubin 
to 2 mg/dl (normal is up to 0.25 mg/dl). The case was referred to the 
Department of Clinical Pharmacology and Therapeutics, NIMS, for 
antituberculosis (TB) regimen in view of hepatitis.
Advice given
According to CDC guidelines 2003, isoniazid, rifampicin, and 
pyrazinamide can all-cause hepatitis that may result in additional liver 
damage in patients with pre-existing liver disease. However, because of 
effectiveness of these drugs, they should be used if at all possible, even 
in the presence of pre-existing liver disease. However, CDC guidelines 
do not give recommendations with respect to isolated serum bilirubin 
elevation.
According to CDC guidelines, if AST >3 upper normal limits, before 
initiation of treatment, treatment options are as follows:
a. Rifampicin, pyrazinamide, and ethambutol (RZE) for 6 months RZE
b. Isoniazid, rifampicin, and ethambutol (HRE) for 9 months HRE
c.	 Rifampicin	+	Ethambutol	 for	12	months	with	fluoroquinolone	for	
the	first	2	months




A 38-year-old female patient is a known case of scleroderma, rheumatoid 
arthritis, and moderate pulmonary arterial hypertension. She was 
started on tablet terbinafine for cutaneous fungal infection. The patient 
was started with empirical ATT 23 days after starting terbinafine. It was 
seen that serum glutamic oxaloacetic transaminase (SGOT) increased to 
245U/L (normal 5 to 40 U/L) and serum glutamic pyruvic transaminase 
(SGPT) to 124 U/L (normal 7–56 U/L) after 2 weeks. The patient was 
started	 on	 liver	 friendly	 regimen	 subsequently,	 which	 consisted	 of	
tab. ethambutol 800 mg, tablet levofloxacin 150 mg, and injection 
streptomycin 750 mg IM daily. She was then referred to the Department 
of Clinical Pharmacology and Therapeutics, NIMS, for advice.
Advice given
Among the drugs prescribed, terbinafine, isoniazid, rifampicin, and 
pyrazinamide are reported to cause hepatotoxicity. In this case, 
according to CDC guidelines as SGOT/SGPT raised to more than 3 
times the ULN with symptoms, isoniazid, rifampicin, and pyrazinamide 
should be withdrawn.
Rechallenge may be planned, when liver function tests were <2 times 
ULN with one drug at a time under supervision by hospitalization 
and intense monitoring of liver function tests. Rifampicin increases 
clearance of terbinafine by 100%. Hence, terbinafine efficacy may be 
reduced and needs to be avoided when coadministered with rifampicin.
CASE NUMBER 3
A 31-year-old female patient came with arthralgia and skin lesion, 
provisional diagnosis of systemic lupus erythematosus was made. She 
developed seizures and was hospitalized. She had hydrocephalus on 
computed tomography scan and pulmonary infiltrates were seen on 
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chest X-ray and was started on ATT empirically. After 3 weeks, ATT-
induced hepatitis was diagnosed with SGOT-320 U/L, SGPT 137 U/L, 
and total bilirubin/direct bilirubin 3.3/3.1 mg/dl. The patient was 
given	 injection	 dexamethasone	 and	 subsequently	 developed	 acute	
psychosis. Review opinion was sought regarding modified ATT in 
view	 of	 hepatitis	 and	 seizures	 (as	 fluoroquinolones	 reduce	 seizure	
threshold).
Advice given
This is suspected case of central nervous system (CNS) TB with ATT 
induced hepatitis (SGOT increased to 5 times upper normal limits and 
increased bilirubin). According to British Thoracic Society guidelines 
for CNS TB 2009, in such cases, pyrazinamide may be withdrawn, but 
in this case as bilirubin is elevated, rifampicin also may be stopped. The 
patient should be started on isoniazid, ethambutol, and amikacin. Liver 
function tests should be monitored daily and rechallenge be started 
with rifampicin, once SGOT is <2 times the ULN value.
DISCUSSION
DILI predisposes a patient to develop drug resistant TB. Recurrence 
of ATT-induced DILI is reported in 10% of cases [3].  Hence, this ATT-
induced DILI should be treated promptly.
Once the diagnosis of DILI due to ATT is established, it is essential 
to first stop all potentially hepatotoxic drugs till complete clinical 
and biochemical resolution of hepatotoxicity occurs. In the interim 
period, at least three non-hepatotoxic drugs such as ethambutol, 
streptomycin,	 and	 quinolones	 such	 as	 levofloxacin	 or	 ofloxacin	
or ciprofloxacin can be used after appropriate evaluation of renal 
function and visual acuity.
According to CDC guidelines, suspected anti-TB drugs can be started 
one at a time once the transaminase levels return to <2 times the upper 
normal. Rifampicin is to be restarted first. If the liver functions remain 
normal after 1 week, isoniazid can be added to the regimen. If the liver 
functions remain normal after 1 week, then pyrazinamide is added. If 
there is recurrence of symptoms or deterioration of liver functions, 
the last added drug should be stopped. Depending on the number of 
doses taken, bacteriological status, and the severity of the disease, the 
treatment may have to be individualized and extended [4].
CONCLUSION
This case series suggest the importance of monitoring of liver function 
tests during the first 8 weeks of use of antitubercular drugs and also 
helps the clinician’s awareness regarding the treatment modalities to 
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